Climb Bio Inc. outlined May 5 an enticing data spill ahead this year with Fc-enhanced monoclonal antibody budoprutug (budo) ...

A designed chimeric virus induced broadly neutralizing antibodies (bNAbs) against the macaque equivalent of HIV. The strategy ...

Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash deal worth $4.1 billion. The acquisition ...

News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the ...

Clinical updates for biopharma and med tech, including data readouts and publications: Aptevo, Atossa, Avalo, Bioxodes, Braintree, Cairn Surgical, Eupraxia, Helio ...

Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry into the cell. This is the first time ...

In its first substantial M&A transaction since 2021, Bayer AG is buying Perfuse Therapeutics Inc., a firm that has operated quietly, though it reported positive midstage data last year for PER-001, an ...

It’s a sure bet when the U.S. Trade Representative releases its annual Special 301 Report that Chile, China, India, Indonesia, Russia and Venezuela will be on the Priority Watch List. The 2026 report ...

Researchers from Alzecure Pharma AB and collaborators reported preclinical efficacy data on ACD-137, a selective negative allosteric TrkA modulator in models of peripheral neuropathy and ...

Biopharma financing activity is continuing its rebound in early 2026 compared to the past several years. Total funding reached $38.66 billion in the first four months of 2026, more than doubling ...

(NASDAQ:AVTX) were trading at $21.78, up almost 34%, or $5.52, on positive top-line results from the phase II Lotus trial evaluating the efficacy and safety of abdakibart in adults with moderate to ...

The classic origin story for a biotech startup is that of a scientist who nurtures his work out of a university and to ...